[go: up one dir, main page]

MXPA02012493A - 1-aril-4-oxo, 1,4-dihidro-3-quinolincarboxamidas como agentes antivirales. - Google Patents

1-aril-4-oxo, 1,4-dihidro-3-quinolincarboxamidas como agentes antivirales.

Info

Publication number
MXPA02012493A
MXPA02012493A MXPA02012493A MXPA02012493A MXPA02012493A MX PA02012493 A MXPA02012493 A MX PA02012493A MX PA02012493 A MXPA02012493 A MX PA02012493A MX PA02012493 A MXPA02012493 A MX PA02012493A MX PA02012493 A MXPA02012493 A MX PA02012493A
Authority
MX
Mexico
Prior art keywords
antiviral agents
quinolinecarboxamides
dihydro
oxo
aryl
Prior art date
Application number
MXPA02012493A
Other languages
English (en)
Inventor
Mark E Schnute
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of MXPA02012493A publication Critical patent/MXPA02012493A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

La presente invencion provee compuestos de la formula (I); (Ver formula) que son utiles como agentes antivirales, particularmente como agentes contra los virus de la familia herpesvirus.
MXPA02012493A 2000-06-16 2001-06-05 1-aril-4-oxo, 1,4-dihidro-3-quinolincarboxamidas como agentes antivirales. MXPA02012493A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21220200P 2000-06-16 2000-06-16
US27213601P 2001-02-28 2001-02-28
PCT/US2001/016481 WO2001098275A2 (en) 2000-06-16 2001-06-05 1-aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents

Publications (1)

Publication Number Publication Date
MXPA02012493A true MXPA02012493A (es) 2003-04-25

Family

ID=26906879

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02012493A MXPA02012493A (es) 2000-06-16 2001-06-05 1-aril-4-oxo, 1,4-dihidro-3-quinolincarboxamidas como agentes antivirales.

Country Status (13)

Country Link
US (2) US6653307B2 (es)
EP (1) EP1292575A2 (es)
JP (1) JP2004501138A (es)
KR (1) KR20030062235A (es)
CN (1) CN1432001A (es)
AR (1) AR030698A1 (es)
AU (2) AU2001268075B2 (es)
BR (1) BR0111729A (es)
CA (1) CA2410452A1 (es)
MX (1) MXPA02012493A (es)
NZ (1) NZ523170A (es)
PE (1) PE20011349A1 (es)
WO (1) WO2001098275A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100375742C (zh) * 2002-11-20 2008-03-19 日本烟草产业株式会社 4-氧代喹啉化合物及其用途
SI1564210T1 (sl) 2002-11-20 2010-01-29 Japan Tobacco Inc 4-oksokinolinske spojine in njihova uporaba kot inhibitorji HIV integraze
US20070185007A1 (en) 2003-09-19 2007-08-09 Haolun Jin Aza-quinolinol phosphonate integrase inhibitor compounds
DE602005010413D1 (de) * 2004-04-14 2008-11-27 Zhenhong R Cai Phosphonatanaloga von hiv-integrasehemmerverbindungen
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2005113509A1 (en) 2004-05-20 2005-12-01 Japan Tobacco Inc. Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
US8633219B2 (en) * 2004-05-21 2014-01-21 Japan Tobacco Inc. Combination therapy
WO2007082946A1 (en) * 2006-01-23 2007-07-26 Novartis Ag Solid forms of a pyrrolopyrimidine derivative and their use as anti-tumor agents
JP2009525261A (ja) * 2006-02-01 2009-07-09 日本たばこ産業株式会社 レトロウイルス感染症の治療のための、６−（３−クロロ−２−フルオロベンジル）−１−［（２ｓ）−１−ヒドロキシ−３−メチルブタン−２−イル］−７−メトキシ−４−オキソ−１，４−ジヒドロキノリン−３−カルボン酸またはその塩の使用
MX2008011457A (es) 2006-03-06 2008-09-24 Japan Tobacco Inc Metodo para producir un compuesto de 4-oxoquinolina.
CN101437801B (zh) 2006-03-06 2013-02-06 日本烟草产业株式会社 制备4-氧代喹啉化合物的方法
WO2011004389A2 (en) 2009-06-18 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of elvitegravir
US9382208B1 (en) 2015-01-26 2016-07-05 Vanderbilt University Negative allosteric modulators of metabotropic glutamate receptor 2
US10495175B2 (en) * 2017-08-08 2019-12-03 Ford Global Technologies, Llc Composite materials having embedded metal ropes for increased damping capacity and methods of manufacturing same
CN108892639B (zh) * 2018-08-13 2021-05-14 云南民族大学 一种高效环保制备喹诺酮类化合物的方法
EP3849979A1 (en) 2018-09-12 2021-07-21 Novartis AG Antiviral pyridopyrazinedione compounds
TW202535873A (zh) 2019-09-26 2025-09-16 瑞士商諾華公司 抗病毒吡唑并吡啶酮化合物
CN119613333A (zh) * 2024-12-05 2025-03-14 湖北大学 一类喹诺酮类化合物及其抗病毒应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1191443A (en) 1968-02-23 1970-05-13 Warner Lambert Pharmaceutical Quinoline Derivatives
US4786664A (en) 1987-03-26 1988-11-22 General Electric Company Compatible polyphenylene ether-linear polyester blends having improved coefficient of thermal expansion
DE3811341A1 (de) 1987-10-09 1989-04-27 Bayer Ag In 7-stellung c-verknuepfte chinolon- und 1,8-naphthyridin-4-on-carbonsaeure und ein verfahren zu ihrer herstellung
JPH02124871A (ja) 1988-07-27 1990-05-14 Dainippon Pharmaceut Co Ltd １位が置換された複素環式カルボン酸アミド誘導体
US4939290A (en) 1988-11-23 1990-07-03 Pfizer Inc. Benzoic acid derivatives
US4959363A (en) 1989-06-23 1990-09-25 Sterling Drug Inc. Quinolonecarboxamide compounds, their preparation and use as antivirals.
GB2236751B (en) 1989-10-14 1993-04-28 Wyeth John & Brother Ltd Heterocyclic compounds
US5175151A (en) 1990-09-07 1992-12-29 Schering Corporation Antiviral compounds and antihypertensive compounds
EP0531578B1 (en) 1991-09-10 1995-12-20 Agfa-Gevaert N.V. Thermally transferable fluorescent compounds
DE4303657A1 (de) 1993-02-09 1994-08-11 Bayer Ag Neue Chinolon- und Naphthyridoncarbonsäurederivate
US5622967A (en) 1993-04-26 1997-04-22 Sterling Winthrop, Inc. Quinolone carboxamide Calpain inhibitors
BR9509768A (pt) 1994-11-24 1998-07-07 Hoffmann La Roche Novas pirimidinas de benzila
DE69631423T2 (de) 1995-08-02 2004-12-02 Darwin Discovery Ltd., Slough Chinolone und deren therapeutische verwendung
EP0841929B1 (en) 1995-08-02 2003-05-07 Darwin Discovery Limited Quinolones and their therapeutic use
CA2250908C (en) 1996-04-30 2012-03-13 Takeda Chemical Industries, Ltd. Combined use of gnrh agonist and antagonist
US6130231A (en) 1996-11-27 2000-10-10 Dupont Pharmaceuticals Integrin receptor antagonists
CA2271136C (en) 1996-11-28 2008-11-25 Wakunaga Pharmaceutical Co., Ltd. Novel pyridonecarboxylic acid derivatives or salts thereof and drugs containing the same as the active ingredient
US6093732A (en) 1997-12-22 2000-07-25 Pharmacia & Upjohn Company 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
IL151787A0 (en) * 2000-03-21 2003-04-10 Upjohn Co 4-oxo-1,4-dihydro-3-cinnolinecarboxamides as antiviral agents

Also Published As

Publication number Publication date
CA2410452A1 (en) 2001-12-27
JP2004501138A (ja) 2004-01-15
US20020103220A1 (en) 2002-08-01
AU2001268075B2 (en) 2005-08-18
KR20030062235A (ko) 2003-07-23
NZ523170A (en) 2004-10-29
PE20011349A1 (es) 2002-01-19
BR0111729A (pt) 2003-07-29
WO2001098275A2 (en) 2001-12-27
WO2001098275A3 (en) 2002-07-04
CN1432001A (zh) 2003-07-23
US20040024209A1 (en) 2004-02-05
AR030698A1 (es) 2003-09-03
US6653307B2 (en) 2003-11-25
AU6807501A (en) 2002-01-02
EP1292575A2 (en) 2003-03-19

Similar Documents

Publication Publication Date Title
MXPA02012493A (es) 1-aril-4-oxo, 1,4-dihidro-3-quinolincarboxamidas como agentes antivirales.
MXPA03011197A (es) Benzoilsufonamidas y sulfonilbenzamidinas que se usan como agentes antitumorales.
PL369530A1 (en) Chemical compounds
MXPA04003886A (es) Tiofen- y tiazolsulfonamidas como agentes antineoplasticos.
WO2002004444A3 (en) Heterocycle carboxamides as antiviral agents
AU2003228770A8 (en) Substituted pyrazolopyrimidines
GB0011203D0 (en) Chemical compounds
MY128458A (en) Antiviral azaindole derivatives
MY117789A (en) Pyrroloquinolones as antiviral agents
WO2002004443A3 (en) Heterocycle carboxamides as antiviral agents
TR200101906T2 (tr) Antiviral ajanlar olarak kuinolinkarboksamitler
DK1200418T3 (da) Nematodicide trifluorbutener
ATE332301T1 (de) Antivirale pyrazolopyridin verbindungen
WO2004014893A3 (en) Antimicrobial aza-bicyclic derivates, their compositions and uses
DE60112330D1 (en) Pyrazolopyridinderivate
MXPA02012042A (es) Compuestos efectivos como agonistas de beta-2-adrenorreceptor, y como inhibidores de pde4.
MXPA03002911A (es) Compuestos quimicos.
TR200402534T4 (tr) Viral enfeksiyonların tedavisinde yararlı oksazinokuinolonlar.
IL158324A0 (en) Arylsulphonamides as anttiviral agents
MXPA01008346A (es) Compuestos quimicos.
MXPA04006041A (es) Antivirales de piridoquinoxalina.
MXPA03009602A (es) Analogos de nociceptina.
WO2001025239A3 (en) Oxazinoquinolones useful for the treatment of viral infections
DE60201074D1 (en) Pyrazolopyridinderivate
SE9904128D0 (sv) Novel compounds

Legal Events

Date Code Title Description
FA Abandonment or withdrawal